MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208

MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208

MARTINSRIED / MUNICH, Germany, Oct. 22, 2013 (GLOBE NEWSWIRE) --

MorphoSys  AG (FSE: MOR;  Prime Standard Segment,  TecDAX, OTC: MPSYY) announced
today  that the  US Patent  and Trademark  Office (USPTO)  has granted  a patent
covering  the Company's cancer  compound MOR208. The  new patent (US 8,524,867)
covers  the antibody's protein  sequence as well  as pharmaceutical compositions
comprising  the same. The  new patent has  a scheduled expiry  date in 2029, not
including  any potential patent office or regulatory extensions, and is licensed
to MorphoSys AG from Xencor, Inc.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "We are
very  optimistic  about  the  prospects  of  MOR208  and  are  building  a  rich
scientific,  medical and commercial package around this program, in order to lay
the groundwork for future commercialization."

MOR208  is a  humanized monoclonal  antibody that  targets the  antigen CD19 for
treatment  of B cell malignancies and autoimmune diseases. The antibody has been
engineered  to possess  significantly enhanced  antibody-dependent cell-mediated
cytotoxicity  (ADCC), thus improving a key  mechanism for tumor cell killing and
offering  potential for enhanced efficacy compared to traditional antibodies for
the treatment of cancer.

MOR208  has shown in  a Phase 1/2a trial  encouraging signs of preliminary anti-
tumor  activity and  an acceptable  safety and  tolerability profile in patients
with  high-risk, heavily pretreated chronic  lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL). The study results showed an overall response rate of
29.6% (according  to IWCLL 2008 criteria) based on  the safety population of the
trial  (n=27).  MorphoSys  is  conducting  Phase  2 clinical trials of MOR208 in
patients  with  non-Hodgkin's  lymphoma  (NHL)  and  B-cell  acute lymphoblastic
leukemia (B-ALL).



About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together  with its  pharmaceutical partners,  MorphoSys has  built a therapeutic
pipeline  of more  than 80 human  antibody drug  candidates for the treatment of
cancer,  rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its  ongoing  commitment  to  new  antibody  technology  and  drug  development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com


HuCAL(®),  HuCAL GOLD(®), HuCAL  PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®)
and  Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.

Slonomics(®)  is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a
subsidiary of MorphoSys AG.


This  communication contains  certain forward-looking  statements concerning the
MorphoSys  group of  companies. The  forward-looking statements contained herein
represent  the judgment of MorphoSys as of  the date of this release and involve
risks  and  uncertainties.  Should  actual  conditions differ from the Company's
assumptions,  actual  results  and  actions  may  differ from those anticipated.
MorphoSys  does not intend to update  any of these forward-looking statements as
far as the wording of the relevant press release is concerned.



For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Media Release (PDF): http://hugin.info/130295/R/1737008/582252.pdf

[HUG#1737008]
 
Press spacebar to pause and continue. Press esc to stop.